This is related to a method of treatment of pain in a patient using a transdermal Therapeutic System for transdermal Administration of buprenorphine for 7 days on the skin of a patient,Said transdermal Therapeutic System comprising an Adhesive Layer containing buprenorphine Structure comprising a layer of Waterproof backing) to buprenorphine, and (b) a Matrix Layer containing buprenorphine on the back-up Layer impermeable to buprenorphine, CA Pa Matrix comprising a base Polymer, (b) buprenorphineAnd (c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, Linolenic Acid, levulinic acid, and mixtures thereof, in an amount sufficient to that buprenorphine is Solubilized therein to form a mixture, and the mixture of carboxylic acid B Uprenorfina form deposits scattered on the base PolymerAnd (c) a skin contact Layer on the Matrix Layer containing buprenorphine, which comprises a Pressure Sensitive Adhesive base Polymer, and, Optionally, where the structure of the self-adhesive Layer containing buprenorphine contains buprenorphine in a quantity of less than 0.8 mg / cm2 basis of buprenorphine or an equimolar amount of a pharmaceutically acceptable Salt of the same.La presente se relaciona con un método de tratamiento del dolor en un paciente al aplicar un sistema terapéutico transdérmico para la administración transdérmica de buprenorfina por 7 días sobre la piel de un paciente, dicho sistema terapéutico transdérmico comprendiendo una estructura de capa autoadhesiva conteniendo buprenorfina que comprende A) una capa de respaldo impermeable a la buprenorfina, y B) una capa matricial conteniendo buprenorfina sobre dicha capa de respaldo impermeable a la buprenorfina, la capa matricial comprendiendo a) una base polimérica, b) buprenorfina, y c) un ácido carboxílico seleccionado del grupo consistente de ácido oleico, ácido linoleico, ácido linolénico, ácido levulínico y mezclas de los mismos, en una cantidad suficiente para que dicha buprenorf
